Article
Chemistry, Multidisciplinary
Kaori Shimizu, Shosaku Kashiwada, Masanori Horie
Summary: This study found that silver nanoparticles can induce cellular oxidative stress and enhance chemokine expression. Different types of silver nanoparticles have different effects on cellular uptake and intracellular effects.
APPLIED SCIENCES-BASEL
(2022)
Article
Oncology
Eshita Khera, Shujun Dong, Haolong Huang, Laureen de Bever, Floris L. van Delft, Greg M. Thurber
Summary: After several clinical failures, anti-body-drug conjugates (ADC) have recently achieved significant progress, with seven new FDA approvals in the last 3 years. The shift towards mechanistically informed ADC design has played a key role in these successes. However, there are still fundamental aspects of ADC design that are not fully understood, such as payload distribution. This study used tumor spheroids and pharmacodynamic marker staining to evaluate tissue penetration of different classes of ADC agents. The results show that the physicochemical properties and potency of the payload can significantly affect tissue penetration and bystander potential.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Oncology
Fengmei Song, Yongxian Hu, Yanlei Zhang, Mingming Zhang, Tingting Yang, Wenjun Wu, Simao Huang, Huijun Xu, Alex H. Chang, He Huang, Guoqing Wei
Summary: This study evaluates the safety and efficacy of humanized CD19-targeted CAR-T cell (hCART19) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). The results show that 93.1% of patients achieved complete remission or remission with incomplete count recovery by day 28, with a median follow-up of 13.5 months. The 1-year overall survival and event-free survival rates were 73.6% and 46.0% respectively, with manageable toxicities.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Hematology
Max Yano, Chia Sharpe, J. Rachel Lance, Janani Ravikrishnan, Kevan Zapolnik, Xiaokui Mo, Jennifer A. Woyach, Deepa Sampath, Adam S. Kittai, Sumithira Vasu, Seema Bhat, Kerry A. Rogers, Dean A. Lee, Natarajan Muthusamy, John C. Byrd
Summary: Stimulation with feeder cells expressing mbIL-21 can rapidly expand both healthy donor-derived and CLL patient-derived NK cells, which exhibit potent cytotoxic activity against CLL cells. Combination with anti-CD20 antibodies greatly enhances NK recognition and killing of CLL targets. The use of mbIL-21-expanded NK cells in combination with obinutuzumab and venetoclax shows efficacy in xenograft mouse models of CLL.
Article
Medicine, General & Internal
Lorena Vigon, Adrian Sanchez-Tornero, Sara Rodriguez-Mora, Javier Garcia-Perez, Magdalena Corona de Lapuerta, Lucia Perez-Lamas, Guiomar Casado-Fernandez, Gemma Moreno, Montserrat Torres, Elena Mateos, Maria Aranzazu Murciano-Anton, Jose Alcami, Mayte Perez-Olmeda, Javier Lopez-Jimenez, Valentin Garcia-Gutierrez, Mayte Coiras
Summary: Oncohematological patients have a reduced immune response to SARS-CoV-2, both from natural infection and vaccination. This study examined the immune response in individuals who underwent chemotherapy and autologous stem cell transplantation (ASCT) after natural infection. It was found that the humoral response was limited prior to ASCT, but an enhanced cellular immune response was observed after chemotherapy plus ASCT.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Milad J. Alasady, Alexander R. Terry, Adam D. Pierce, Michael C. Cavalier, Catherine S. Blaha, Kaylin A. Adipietro, Paul T. Wilder, David J. Weber, Nissim Hay
Summary: Elevated S100B in malignant melanoma reduces IL6-STAT3 signaling through the RSK signaling pathway, affecting IL6 expression.
Review
Cell & Tissue Engineering
Sabiha Shamim, Nasar Khan, David L. Greene, Umm E. Habiba, Amna Umer
Summary: This article summarizes the current trends and outcomes of clinical trials using autologous and allogeneic cellular approaches to investigate the use of cellular therapies in treating autism spectrum disorder (ASD). Stem-cell therapy has shown improvements in outcome measures for patients with ASD, but more research is needed to confirm these results. The article evaluates data from published trials and proposes further steps for pursuing this field of research.
REGENERATIVE MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Norio Nakagawa, Ken Kikuchi, Shigeki Yagyu, Mitsuru Miyachi, Tomoko Iehara, Tatsuro Tajiri, Toshiyuki Sakai, Hajime Hosoi
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2019)
Article
Oncology
Kazutaka Ouchi, Mitsuru Miyachi, Shigeki Yagyu, Ken Kikuchi, Yasumichi Kuwahara, Kunihiko Tsuchiya, Tomoko Iehara, Hajime Hosoi
CANCER CELL INTERNATIONAL
(2020)
Article
Oncology
Yohei Sugimoto, Yoshiki Katsumi, Tomoko Iehara, Daisuke Kaneda, Chihiro Tomoyasu, Kazutaka Ouchi, Hideki Yoshida, Mitsuru Miyachi, Shigeki Yagyu, Ken Kikuchi, Kunihiko Tsuchiya, Yasumichi Kuwahara, Toshiyuki Sakai, Hajime Hosoi
MOLECULAR CANCER THERAPEUTICS
(2020)
Article
Oncology
Hiroshi Kubo, Shigeki Yagyu, Kayoko Nakamura, Kumiko Yamashima, Akimasa Tomida, Ken Kikuchi, Tomoko Iehara, Yozo Nakazawa, Hajime Hosoi
Summary: EPHB4, a target in tumors like rhabdomyosarcoma, can be effectively targeted by EPHB4-specific CAR-T cells using the natural ligand EPHRIN B2. These CAR-T cells showed promising results in killing tumor cells and suppressing tumor growth without activating downstream cell proliferation mechanisms.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Multidisciplinary Sciences
Takuyo Kanayama, Mitsuru Miyachi, Yohei Sugimoto, Shigeki Yagyu, Ken Kikuchi, Kunihiko Tsuchiya, Tomoko Iehara, Hajime Hosoi
Summary: The study found that PAX3-FOXO1 is associated with B7-H3 in alveolar rhabdomyosarcoma, with PAX3-FOXO1 positively regulating B7-H3 expression. Both are involved in multiple pathways related to aggressiveness in ARMS, such as cell migration and myogenic differentiation.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Satoshi Miyagaki, Ken Kikuchi, Jun Mori, Gary D. Lopaschuk, Tomoko Iehara, Hajime Hosoi
Summary: Inhibition of lipid metabolism in rhabdomyosarcoma cells decreases cell proliferation and low-fat diet in vivo studies shows reduced tumor growth. Disruption of lipid metabolism alters the equilibrium of cancer-specific metabolism and inhibits tumor growth in rhabdomyosarcoma.
Article
Biology
Carla Regina, Ebrahem Hamed, Geoffroy Andrieux, Sina Angenendt, Michaela Schneider, Manching Ku, Marie Follo, Marco Wachtel, Eugene Ke, Ken Kikuchi, Anton G. Henssen, Beat W. Schafer, Melanie Boerries, Amy J. Wagers, Charles Keller, Simone Hettmer
Summary: The study shows that heterogeneous expression of PAX3:FOXO1 at the single cell level in rhabdomyosarcoma cells may provide a critical advantage during tumor progression.
LIFE SCIENCE ALLIANCE
(2021)
Article
Oncology
Tatsushi Yoshida, Kenta Yamasaki, Kenjiro Tadagaki, Yasumichi Kuwahara, Akifumi Matsumoto, Adem Ejub Sofovic, Noriko Kondo, Toshiyuki Sakai, Tsukasa Okuda
Summary: The study identified RUNX1 as a transcriptional regulator of TRAIL, showing that TRAIL expression is decreased in acute myeloid leukemia patients and inhibited by RUNX1-ETO.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2022)
Article
Pediatrics
Daisuke Kaneda, Tomoko Iehara, Ken Kikuchi, Yohei Sugimoto, Norio Nakagawa, Shigeki Yagyu, Mitsuru Miyachi, Eiichi Konishi, Toshiyuki Sakai, Hajime Hosoi
Summary: OBP-801 induces M-phase arrest and apoptosis in neuroblastoma cells via mitotic catastrophe, making it a promising therapeutic agent with fewer adverse effects for patients with neuroblastoma.
PEDIATRICS INTERNATIONAL
(2022)
Article
Oncology
Haruka Shinohara, Rie Sawado, Makoto Nakagawa, Ayuna Hattori, Kazutsune Yamagata, Kimiharu Tauchi, Jumpei Ito, Yasumichi Kuwahara, Tsukasa Okuda, Chitose Ogawa, Issay Kitabayashi
Summary: This study found that both EZH1 and EZH2 are potential targets for therapy in malignant rhabdoid tumors (MRT), and dual inhibition of EZH1/2 may be a promising therapeutic strategy for MRT.
MOLECULAR THERAPY-ONCOLYTICS
(2022)
Article
Biochemistry & Molecular Biology
Masamitsu Mikami, Tatsuya Masuda, Takuya Kanatani, Mina Noura, Katsutsugu Umeda, Hidefumi Hiramatsu, Hirohito Kubota, Tomoo Daifu, Atsushi Iwai, Etsuko Yamamoto Hattori, Kana Furuichi, Saho Takasaki, Sunao Tanaka, Yasuzumi Matsui, Hidemasa Matsuo, Masahiro Hirata, Tatsuki R. Kataoka, Tatsutoshi Nakahata, Yasumichi Kuwahara, Tomoko Iehara, Hajime Hosoi, Yoichi Imai, Junko Takita, Hiroshi Sugiyama, Souichi Adachi, Yasuhiko Kamikubo
Summary: This study identifies the importance of the interaction between RUNX1 and survivin in the proliferation of MRT cells, providing a potential target for novel anti-tumor therapies.
MOLECULES AND CELLS
(2022)
Article
Oncology
Tomoo Daifu, Masamitsu Mikami, Hidefumi Hiramatsu, Atsushi Iwai, Katsutsugu Umeda, Mina Noura, Hirohito Kubota, Tatsuya Masuda, Kana Furuichi, Saho Takasaki, Yuki Noguchi, Ken Morita, Toshikazu Bando, Masahiro Hirata, Tatsuki R. Kataoka, Tatsutoshi Nakahata, Yasumichi Kuwahara, Tomoko Iehara, Hajime Hosoi, Junko Takita, Hiroshi Sugiyama, Souichi Adachi, Yasuhiko Kamikubo
Summary: Malignant rhabdoid tumor (MRT) is a rare and highly aggressive pediatric malignancy with poor prognosis. Current therapies are not effective enough, making the inhibition of RUNX1 a potential novel strategy for MRT treatment.
PEDIATRIC BLOOD & CANCER
(2021)
Article
Oncology
Yasumichi Kuwahara, Tomoko Iehara, Eisuke Ichise, Yoshiki Katsumi, Kazutaka Ouchi, Kunihiko Tsuchiya, Mitsuru Miyachi, Eiichi Konishi, Hiroyasu Sasajima, Satoaki Nakamura, Shigehisa Fumino, Tatsuro Tajiri, Pascal D. Johann, Michael C. FrUhwald, Tatsushi Yoshida, Tsukasa Okuda, Hajime Hosoi
ANTICANCER RESEARCH
(2020)
Article
Oncology
Tomoko Iehara, Shigeki Yagyu, Takahiro Gotoh, Kazutaka Ouchi, Hideki Yoshida, Mitsuru Miyachi, Ken Kikuchi, Tohru Sugimoto, Hajime Hosoi
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2019)